0001309057 false NONE 0001309057 2023-10-23 2023-10-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 23, 2023

 


 

CHINA HEALTH INDUSTRIES HOLDINGS, INC.
(Exact name of Registrant as specified in its Charter)

 


 

Delaware   000-51060   86-0827216

(State or other jurisdiction

of incorporation)

  (Commission File No.)  

(IRS Employer

Identification No.)

 

3199-1 Longxiang Road, Songbei District
Harbin City, Heilongjiang Province
People’s Republic of China, 150028
(Address of principal executive offices) (Zip Code)

 

86-451-88100688
(Registrant’s Telephone Number)

 

Not Applicable
(Former name or address, if changed since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Not Applicable Not Applicable Not Applicable

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2) 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act 

 

 

 

 

ITEM 4.01. CHANGES IN REGISTRANT’S CERTIFYING ACCOUNTANT.

 

On October 23, 2023, the Board of Directors of China Health Industries Holdings, Inc., a corporation incorporated under the laws of the State of Delaware (the “Company”) approved the dismissal of ARK Pro CPA & Co. (“ARK”) as the Company’s independent registered public accounting firm, effective immediately.

 

ARK was engaged on August 2, 2023, after the most recent fiscal year of the Company. As a result, there has been no report issued by ARK on any financial statements of the Company as of October 23, 2023. 

 

During the period from August 2, 2023, the date on which ARK was engaged through October 23, 2023 (the “ARK Engagement Period”), there were no disagreements with ARK on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement(s), if not resolved to the satisfaction of ARK, would have caused it to make reference to the subject matter of the disagreement(s) in connection with its report. During the ARK Engagement Period, there were no reportable events of the type described in Item 304(a)(1)(v) of Regulation S-K.

 

The Company provided ARK with a copy of the foregoing disclosure and requested ARK to furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made therein. A copy of such letter furnished by ARK is filed as Exhibit 16.1 to this Form 8-K.

 

On October 23, 2023, the Board of Directors of the Company approved the engagement of Assentsure PAC (“Assentsure”) as its new independent registered public accounting firm.

 

During the Company’s two most recent fiscal years and the subsequent interim period through October 23, 2023, neither the Company nor anyone on its behalf consulted with Assentsure regarding (i) the application of accounting principles to a specified transaction, either completed or proposed; the type of audit opinion that might be rendered on the Company's financial statements, and neither a written report nor oral advice was provided that Assentsure concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and its related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

 

(d) Exhibits.

 

Exhibit No.   Description
16.1   Letter from ARK Pro CPA & Co. dated October 24, 2023
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CHINA HEALTH INDUSTRIES HOLDINGS, INC.
   
Date: October 24, 2023 /s/ Xin Sun
   By: Xin Sun
   Title:

Chief Executive Officer and

Chief Financial Officer

(Principal Executive Officer,

Principal Financial Officer and

Principal Accounting Officer)